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Abstract
Background: The Metabolic syndrome (MetS) is a cardiovascular risk factor of public health significance and of
recent has become a topical issue. The prevalence of diabetes mellitus (DM) is on the increase and with this
scenario, a possible increase in burden of DM which may be largely attributed to cardiovascular complications is
expected. The objective of this report is to determine the prevalence of the MetS and compare gender
characteristics in subjects with type 2 DM.
Methods: Subjects with type 2 DM were recruited from an urban hospital for the study. Clinical data was obtained
by interviewing the patients and referring to their Case folders. The anthropometric indices and blood pressure
measurements were documented. Laboratory parameters analysed for included total cholesterol, high density and
low density cholesterol, triglyceride and glycosylated haemoglobin. Statistical analysis included usage of Student’s
t test and chi square.
Results: 963 patients with type 2 DM aged between 35-85 years were recruited for the study. The main outcome
measures included the prevalence of the metabolic syndrome and the gender differences of its components. The
prevalence of the metabolic syndrome was 86%. The frequency of occurrence of the MetS was similar for men
(83%) and women (86%) and increased with age in both sexes. The prevalence of MetS increased from 11%
among participants aged 20 through 29 years to 89% in participants aged 70 through 79. In our patients with DM,
the commonest occurring and least detected MetS defining parameters are central obesity and elevated
triglyceride levels respectively. The components of the MetS that differed significantly in both sexes was HDL-C.
The combination of the components of the MetS were comparable in both genders and 5.8% of the subjects with
the MetS had all components of the MetS.
Conclusion: The prevalence of the MetS in type 2DM is high in both genders and increases with age thus posing
a potential high cardiovascular risk in this group of patients. The modifiable risk factors for the MetS should be a
focus point in the management of subjects with type 2 DM,
Introduction
The metabolic syndrome (MetS) is a cluster of cardiovas-
cular risk factors that is characterized by obesity, central
obesity, insulin resistance, atherogenic dyslipidemia, and
hypertension[1]. Although there are different definitions
of the metabolic syndrome, the uniform pathophysiology
of this syndrome is insulin resistance[2]. A prominent
clinical feature of this syndrome is abdominal or central
obesity. The criteria [3] for the MetS include five vari-
ables namely, abdominal obesity, raised triglycerides, low
high density alcohol (HDL), elevated blood pressure and
a history of diabetes mellitus or impaired fasting glucose
state. The importance of the metabolic syndrome lies lar-
gely in the development of cardiovascular diseases and
type 2 diabetes mellitus[4].
The prevalence of metabolic syndrome increases with
increasing glucose intolerance [5] and with the increas-
ing world wide prevalence of DM, the expected increase
in the frequency of occurrence of the MetS will expect-
edly be in geometric proportions. The prevalence of the
MetS in the general population is estimated to be
between 17-25% [6,7] and in people with DM, reported
prevalence rates range from 59% to 61% [6-8].
In Nigeria, DM is an emerging non-communicable
health problem as its prevalence is on the increase. The
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without DM are 22% and 59% respectively.
Published reports differ in the gender distribution of
the MetS. Whilst some researchers report a higher inci-
dence of the MetS in men [9,10] than women, the
r e v e r s ei st h ec a s ei ns o m eo t h e rr e p o r t s [ 1 1 ] .Ac o n s i s -
tent finding in the prevalence of the metabolic syn-
drome, is age dependence- the prevalence of the MetS
is often noted to increase with age [9,12]. This report
aims to determine the frequency of occurrence, corre-
lates and gender distribution of the components of the
MetS in Nigerians with DM.
Methods
Subjects with type 2 DM were recruited from the Gen-
eral hospital Gbagada and theL a g o ss t a t eU n i v e r s i t y
Teaching hospitals, Lagos for the study. This report is
part of a recent study on lipid profile in DM by the
author [13]. Details of DM including duration, treatment
type, presence of comorbidities, smoking and alcohol
histories were obtained by interviewing the study sub-
jects and also from information in their case folders.
Clinical examination entailed determining the body
mass indices and waist circumferences.
Laboratory assessment included obtaining venous
blood samples in a fasted state for the determination of
components of the lipid panel (total cholesterol, high
density cholesterol, low density cholesterol and triglycer-
ide), blood glucose and glycosylated haemoglobin levels
(HBA1c). Serum glucose was measured using glucose-
oxidase method and lipid profile by enzymatic-colori-
metric method. Ethical approval was obtained from the
Ethical committee of both hospitals and informed con-
sent was obtained from the study subjects.
The presence of the metabolic syndrome was deter-
mined using the new definition[3]. The presence of three
or more of any of the following is a pointer to the MetS.
waist circumference (WC) greater than 102 cm in men
and 88 cm in women; serum triglycerides (TG) level of at
least 150 mg/dL (1.69 mmol/L); high-density lipoprotein
cholesterol (HDL-C) level of less than 40 mg/dL (1.04
mmol/L) in men and 50 mg/dL (1.29 mmol/L) in
women; blood pressure of at least 130/85 mm Hg; or
serum glucose level of at least 100 mg/dL (5.6 mmol/L).
Results
A total of 973 patients with diabetes mellitus were
recruited for the study. The females and males were 703
and 260 in number respectively.
Clinical characteristics of the study subjects
The mean age of the study subjects was 58.6 (10.5) years
and the female:male ratio was 3:1. Smoking and alcohol
histories were documented in 83 (9%) and 208 (21%) of
the subjects. Hypertension was a notable feature which
was present in 572 (59%) of the subjects. A summary of
the clinical parameters of the study subjects is shown in
Table 1:
A comparison of the clinical and biochemical para-
meters of both sexes showed that the mean BMI and
duration of DM of the female subjects were significantly
higher than those of the males (29.5 kg/m
2 vs 27 kg/m
2
p = 0.0001, 7 vs 6.5, p = 0.03). The mean HBA1c, Low
density lipoprotein (LDL-C) and total cholesterol
(TCHOL) were also significantly higher in females than
males respectively (6.7% vs 6.2% p = 0.015, 132.1 mg%
vs117.4 mg% p = 0.02, 192 vs 183 p = 0.001).
Well over half-793- of the subjects (81%) were on oral
hypoglycaemic agents, 64 (7%) were on insulin and 108
(11%) and 9(1%) respectively were on combination of
insulin and OHA and sole dietary management
respectively.
The metabolic syndrome and clustering of its
components
The total number of the subjects with the metabolic
syndrome was 834 thus giving a prevalence rate of 86%.
The most prevalent risk factor was abdominal obesity.
The proportions of the defining parameters of MetS are
shown in Table 2
The distribution of the components of the metabolic
syndrome is depicted in Figure 1:
For two components, the most frequent combinations
were central obesity and reduced HDL-C (51.6% in
women and 57.5% in men), for three components, the
most frequent combinations were central obesity, hyper-
tension and reduced HDL- (42.2% in women and 37.8%
Table 1 Clinical characteristics of the study subjects
Variable Mean (SD*) Range
Age (years) 58.7(9.9) 35-85
BMI(kg/m
2) 28.8(5.9) 14.8-56.9
WC(cm) 94.8 (13.4) 32-165
Duration of DM (years) 6.9(6.6) 0.1-40
HBA1c 6.6(2.4) 3.6-18
*-Standard deviation
Table 2 Frequency of occurrence of the components of
the metabolic syndrome
MetS defining parameters Frequency (%)
Waist circumference component 658 (80%%)
History of hypertension 562(67%)
Elevated Triglyceride 194 (23%)
Reduced high density lipoprotein
cholesterol
576 (69%)
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4.5% in men).
The proportion of the males with the MetS was com-
parable to that of the females with the MetS (83% vs
87%, p-0.2) The mean duration of DM was comparable
in both sexes (7.1(6.2) vs 6.5(6.6) p-0.1). The overall pre-
valence of hypertension was 67% and the proportion of
females with it was significantly higher than that of the
males. (70% vs 605, p-0.04). Smoking and alcohol his-
tories were documented more in males than females
and these differences were statistically significant (for
smoking 11 (2%) vs 60 (27%) p 0.0000001. alcohol his-
tory (71 (12%) vs 105 (47%) p-0.00001)
Pattern of lipid subjects with the metabolic syndrome
The pattern of lipid abnormalities showed that elevated
LDL-C and reduced HDL-C were the commonly docu-
mented lipid abnormalities. This is shown in Figure 2.
The frequency of occurrencep r e v a l e n c eo ft h em e t a -
bolic syndrome increased with age. The proportions of
subjects with the metabolic syndrome in each age class
is shown in Table 3
The age specific distribution of the MetS was compar-
able in both genders except in ages 70 through 79.9.
These results are shown in Figure 3.
The proportion of women with the MetS who had ele-
vated blood pressure was significantly higher than men
who had same (431 (76% vs 135 (61%), p = 0.01).
Females with the metabolic syndrome tended to have
higher total cholesterol andL D L - c h o l e s t e r o lt h a nt h e
males with the metabolic syndrome. A comparison of
other clinical and biochemical parameters in both gen-
ders with the MetS is shown in Table 4
Figure 1 Distribution of the components of the Mets.
Figure 2 Pattern of lipid abnormalities in subjects with the
Mets.
Table 3 Distribution of the metabolic syndrome by age
classes
Age classes All, N (freq) MetS, N (freq)
20-29.9 9 (1%) 1(11%)
30-39.9 39 (4%) 28(72%)
40-49.9 118(12.1%) 97(82%)
50-59.9 271(27.9%) 238(88%)
60-69.9 405(41.6%) 353(87%)
70-79.9 123(12.6%) 110 (89%)
>80 8(0.8%) 7 (87%)
Figure 3 Age-specific gender distribution of the prevalence of
the Mets.
Table 4 Gender differences in clinical and biochemical
parameters of subjects with the MetS
Variable Males: Females_ _p value_
WC(cm) 95.2 (11.9) 96.8 0.1
AGE (years) 60.8(10) 58.7(9.5) 0.05
BMI(kg/m
2) 27.6(4.3) 30 (3) 0.0001
TG(mg%) 105.3 (55) 104.8 (5) 0. 8
CHOL(mg%) 185(43.2) 197.3(46.8) 0.001
LDL-C (mg%) 121(41.6) 133.9(49.9) 0.001
HDL-C (mg%) 40.1(16.5) 43.8 (19) 0.01
Quantitative data are displayed as mean values and standard deviation
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with and without Mets
The subjects with the metabolic syndrome tended to be
older and their mean LDL-C was higher than that of the
subjects without the metabolic syndrome. The clinical
and biochemical parameters are shown in Table 5.
Discussion
The MetS is a cluster of cardiovascular risk factors includ-
ing obesity, hypertension and dyslipidaemia that increases
the risk of the development of type 2 diabetes mellitus and
cardiovascular disease. The risk factors of MetS include
obesity, aging, sedentary lifestyle, diabetes mellitus, coron-
ary heart disease and lipodystrophy [14,15]. It is estimated
that t a large majority of patients with type 2 DM or
impaired glucose tolerance have the metabolic syndrome
[8]. I note similar findings in this study and report the pre-
valence rate of Mets to be 86%. The prevalence rates of
the Mets in both genders as noted in this report are com-
parable to that of a previous report on the Mets[16]. The
role of age as a risk factor of MetS cannot be overempha-
sized as age dependency of the syndrome’sp r e v a l e n c ei s
seen in most populations around the world[6]. In this
report, the prevalence of MetS is noted to increase from
11% among participants aged 20 through 29 years to 89%
in participants aged 70 through 79. Although this study
showed that the mean age of men with MetS was signifi-
cantly higher than that of women, the age specific preva-
lence of MetS however was similar in both genders except
for ages 70-79 where the proportion of men with MetS
was found to be almost twice that of females. These find-
ings are contrary to those documented in a Seychelles’[17]
population where the greatest prevalence of MetS using
the ATP definition was highest at age 45-54 for men. In a
Finnish [18] study on Mets, the prevalence of the MetS
was found to increase with increasing age in women.
There are currently two major definitions for meta-
bolic syndrome and these are provided by the Interna-
tional Diabetes Federation[16] and the revised National
Cholesterol Education Program [19], respectively. In a
bid to harmonize the different criteria for the definition
of the Mets, several bodies have met and issued a joint
statement making some alterations in the International
Diabetes Federation (IDF) definition of the Mets. The
main difference concerns the measure for central obesity
which was proposed should no longer be an obligatory
component for the diagnosis of the Mets although the
waist measurement would continue to be a useful preli-
minary screening tool. The proposed blood glucose cri-
terion as one of the defining parameters of the Mets is
now 100 mg% or more[3].
The components of the metabolic syndrome vary in
their rates of occurrence. The Seychelles[16] study
reported high blood pressure and adiposity as the MetS
defining criteria that occurred most commonly irrespec-
tive of the MetS definitions used. I however report cen-
tral obesity and reduced HDL-cholesterol as the
prevalent components of the Mets in our study subjects.
The mean waist circumferences were comparable in
both sexes with Mets but significantly lower HDL levels
were noted in men than in women. Central obesity was
found in 80% of the study subjects. This finding is not
surprising given the observation that central obesity
plays a central role in the development of the MetS and
appears to precede the appearance of the other MetS
components[20]. It is however pertinent to note that
although the specific role of central obesity in patients
with the metabolic syndrome remains unexplained,
active brown adipocytes which accumulate in central
locations have been found to be metabolically active. In
addition, many studies have confirmed the existence of
a tighter correlation of central obesity with insulin resis-
tance, dyslipidemia, hypertension, and atherosclerotic
heart disease than for obesity without regard to pattern
[21]. Some researchers have report lower rates-25%- of
occurrence of central obesity in the MetS[22].
The pattern of lipid abnormalities in this study was
such that LDL-C although not a component of MetS
was the commonest documented lipid abnormality in
subjects with the MetS. The occurrence of elevated
LDL-C in people with the Mets has been noted to
increase the magnitude of the risk for developing coron-
ary artery disease[23]. I report a gender difference in the
pattern of lipid abnormality in subjects with the Mets.
LDL-C and TCHOL were higher in women than in men
with the MetS. The men with the MetS however had
higher mean TG and lower HDL-C values than women
with the MetS. This pattern of lipid abnormality was
documented in a recent Nigerian study [7].
Gender differences were also documented in the
occurrence of hypertension in the metabolic syndrome.
We report a prevalence rate of hypertension of 67%.
This is similar to reports to reports from the Middle
East[22] and Nigerian reports[7]. There were however
Table 5 Clinical and biochemical parameters of subjects
with the Mets and without the Mets.
Variable MetS Non MetS_____ p value_______
TCHOL(mg%) 193.8(46) 193.7 (48.8) 0.9
LDL-C(mg%) 130.3 (48) 114 (50) 0.001
Age (years) 59.2 (9.9) 55.1 (13.7) 0.001
Smoking 71 (8.5%) 12 (8.7%) 0.9
Alcohol 126 (21%) 32 (23%) 0.1
HBA1c(%) 6.6 (2.4) 7(2.3) 0.08
BMI(kg/m
2) 29.3(29.30 25.8(5.9) 0.00001
Duration of DM
(years)
6.9 (6.5) 7.2(7) 0.3
Quantitative data are displayed as mean values and standard deviation
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females were found to have a significantly higher inci-
dence rates of hypertension than men.
Although each of the components of the metabolic
syndrome individually have been identified as risk fac-
tors for cardiovascular disease, an individual with three
or more components is at particularly high risk. I report
a comparable distribution of the components of the
MetS in both sexes. A small proportion-5.8% -of our
subjects with type 2 DM have all the components of the
MetS. This is in contradistinction to the report by Fezeu
et al[9] who reported the absence of a combination of
four component of the MetS in their study subjects.
Potential factors that may have accounted in the gender
differences in the distribution of the components of the
MetS include an older age in men and significant smok-
ing and alcohol histories.
A comparison of biochemical parameters other than
those that define the MetS in both sexes showed that
subjects with the MetS were significantly older, had
higher body mass indices and higher low density choles-
terol than those without the MetS.
Conclusion
This study has shown the unacceptably high prevalence
rate of MetS in both sexes with type 2 DM thus predict-
ing a high disease burden of type 2 DM from possible
cardiovascular complications.
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